〔Abstract〕 To explore the correlation between the clinical , pathological , genetic features , prognosis , and tumor lymph node metastasis in patients with stage Ⅰ A - Ⅲ B lung invasive non-mucinous adenocarcinoma (INMA) . Methods A retrospective analysis was conducted on 67 eligible patients with INMA . Clinical data , his- topathological assessments , and genetic testing were collected . Disease progression-free survival (PFS) was the pri- mary endpoint through follow-up . The chi-square test or Fisher exact test was used to analyse the correlation be- tween tumour lymph node metastasis and clinicopathological and genetic characteristics . The Cox proportional haz- ards regression model and Kaplan - Meier method were used to analyse the impact of tumour lymph node metastasis on prognosis . Results A total of 67 patients were included , aged 46 - 77 years , with a median age of 61 years . Age , gender , and smoking history were not significantly associated with tumor lymph node metastasis . Larger tumor diameter , tumor progression , and receiving postoperative adjuvant treatment were associated with tumour lymph node metastasis ( P < 0. 05) . Poorer differentiated tumors according to International Association for the Study of Lung Cancer (IASLC) grading system was more likely to have lymph node metastasis (P = 0. 043) . There was no significant difference in the types of driver gene mutations and lymph node metastasis . However , EGFR mutations were more common in patients without lymph node metastasis , while co-mutations were more common in patients with lymph node metastasis . Lymph node metastasis was significantly associated with PFS . Patients without lymph node metastasis had a significantly better PFS compared to those with lymph node metastasis (P = 0. 002) . Under different treatment conditions , patients without lymph node metastasis exhibited a significant advantage in PFS when untreated . While treatment showed a trend toward improved PFS , the difference did not reach statistical signifi- cance . Additionally , no significant differences in PFS were observed between patients with or without lymph node metastasis following chemotherapy or targeted therapy . Conclusion Lymph node metastasis in INMA patients is re- lated to tumor size , progression status , and gene co-mutations , and is a key prognostic indicator affecting PFS .